EP3495387
Tvísértæk and-VEGF/and-ANG-2 mótefni og notkun þeirra við meðferð á æðasjúkdómum í augum
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
11.7.2013EP published:
1.9.2021EP application number:
18184973.8
EP translation filed:
18.10.2021Grant published:
15.11.2021EPO information:
European Patent Register
Max expiry date:
10.7.2033Expiry date:
10.7.2026Next due date:
31.7.2026
Title:
BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES AND THEIR USE IN THE TREATMENT OF OCULAR VASCULAR DISEASES
Timeline
Today
11.7.2013EP application
1.9.2021EP Publication
18.10.2021Translation submitted
15.11.2021Registration published
10.7.2026Expires
Owner
Name:
F. Hoffmann-La Roche AGAddress:
Grenzacherstrasse 124, CH-4070 Basel, CH
Inventor
Name:
DUERR, HaraldAddress:
82377 Penzberg, DE
Name:
HERTING, FrankAddress:
82377 Penzberg, DE
Name:
KLEIN, ChristianAddress:
8952 Schlieren, CH
Name:
REGULA, Joerg ThomasAddress:
81377 Muenchen, DE
Name:
RUETH, MatthiasAddress:
82377 Penzberg, DE
Name:
STUBENRAUCH, Kay-GunnarAddress:
82377 Penzberg, DE
Agent
Name:
Lára Helga SveinsdóttirAddress:
Grundarstíg 23, 101, Reykjavík,
Priority
Number:
12176299Date:
13.7.2012Country:
EP
Supplementary protection
SPC number:
SPC422
Classification
Categories:
C07K 16/22, C07K 16/46, C07K 16/28, A61P 27/02, A61P 27/06
Annual fees
Number
Paid
Expires
Payer
Number: 10
Paid: 15.6.2022
Expires: 10.7.2023
Payer: Árnason Faktor ehf.
Number: 11
Paid: 22.6.2023
Expires: 10.7.2024
Payer: Árnason Faktor ehf.
Number: 12
Paid: 19.6.2024
Expires: 10.7.2025
Payer: Árnason Faktor ehf.
Number: 13
Paid: 7.7.2025
Expires: 10.7.2026
Payer: Árnason Faktor ehf.